Seeking Alpha

Isis Pharmaceuticals (ISIS +3.1%) clearly has something that Biogen Idec (BIIB +1.3%) likes -...

Isis Pharmaceuticals (ISIS +3.1%) clearly has something that Biogen Idec (BIIB +1.3%) likes - the latter adds a third agreement in the companies' partnership, which will now include the development of drugs for three undisclosed targets to treat neurological or neuromuscular disorders. Biogen will pay Isis $30M upfront, another $200M in milestones for each program, and double-digit royalties on drug sales. (PR)
From other sites
Comments (1)
  • arthurs1
    , contributor
    Comments (366) | Send Message
     
    Get in now! Great DD can be found here.
    http://bit.ly/JC0uFl
    10 Dec 2012, 11:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs